Renal disease News and Research

RSS

Study paves the way for new therapeutic targets which can potentially improve heart disease in patients with end-stage kidney failure

Night-time hemodialysis patients may have a greater capacity to repair their hearts and blood vessels compared to those on conventional dialysis three times a week, according to a study in the October issue of the American Journal of Physiology - Renal Physiology, published by the American Physiological Society.

4 Oct 2005

Genetically engineered animals help in scientific research that may benefit children

The recent use of genetically modified mice and rats in combination with an animal model of obstructive nephropathy, a type of renal disease, has given researchers new insight in the development of kidney disease.

21 Sep 2005

Possibility of a continuously functioning, wearable or implantable artificial kidney

Researchers have developed a human nephron filter (HNF) that would eventually make possible a continuously functioning, wearable or implantable artificial kidney.

30 Aug 2005

Experimental immunusuppressant drug preserves transplanted kidneys

An international team of transplant physicians has shown that the investigational drug belatacept (LEA29Y) preserves transplanted kidney function as effectively as cyclosporine, the drug most commonly used to prevent the immune system from rejecting transplanted organs.

24 Aug 2005

Reasons for complications with kidney failure patients

Mayo Clinic researchers searching for explanations of high mortality rates among kidney failure patients undergoing hemodialysis are focusing their attention on the use of heparin, a drug used to reduce clotting of the blood.

18 Aug 2005

Medicare at 40: Past Accomplishments and Future Challenges

As Americans commemorate Medicare's 40th Anniversary, AARP's Public Policy Institute (PPI) has released the report, "Medicare at 40," which examines the program's successes as well as the challenges that lie ahead. It found that Medicare has largely accomplished its original goals of ensuring access to care and establishing financial protections for medical costs.

2 Aug 2005

Diuretics work better than newer and more costly medicines for diabetics with high blood pressure

Diuretics (water pills) work better than newer and more costly medicines in the treatment of high blood pressure and prevention of some forms of heart disease in people with type 2 diabetes, according to results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

28 Jun 2005

Two common gene variations are associated with the risk for developing chronic kidney disease

Two common gene variations are associated with the risk for developing chronic kidney disease, according to a study by researchers at the Johns Hopkins Bloomberg School of Public Health and other institutions. One variant increases risk and the other decreases risk with a similar effect in whites, African-Americans, diabetic and non-diabetic individuals.

14 Jun 2005

Study reveals benefits of using insulin earlier

Results of an all-Canadian study announced June 13 at an international diabetes congress demonstrate that patients with type 2 diabetes can safely achieve target blood sugar (glycemic) levels faster and more frequently when insulin glargine (a basal, long-acting insulin) is added to therapy, versus using oral agents alone.

14 Jun 2005

Unique therapeutic strategy to combat cachexia

Researchers at Oregon Health & Science University's Doernbecher Children's Hospital have uncovered a unique therapeutic strategy to combat cachexia - severe malnutrition and physical wasting away - in children and adults with chronic kidney disease (CKD). The study is published in the June issue of the Journal of Clinical Investigation.

9 Jun 2005

Bone Care International issued new patent

Bone Care International has announced that the U.S. Patent and Trademark Office has issued to it U.S. Patent Number 6,903,083 entitled "Stabilized hydroxyvitamin D."

8 Jun 2005

La Jolla Pharmaceutical provides update on Riquent

La Jolla Pharmaceutical Company today announced that it has received "fast track" designation for Riquent (abetimus sodium) for the treatment of lupus renal disease from the U.S. Food and Drug Administration (FDA).

31 May 2005

Myogen's Ambrisentan granted orphan drug designation by Europeans

Myogen today announced that the Commission of the European Communities, with a favorable opinion of the Committee for Orphan Medicinal Products of the European Medicines Agency (EMEA), has granted orphan drug designation to ambrisentan for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension.

2 May 2005

New guidelines for managing chronic kidney disease in patients living with HIV infection

The HIV Medicine Association has released guidelines for managing chronic kidney disease in patients living with HIV infection. They are published in the June 1 issue of Clinical Infectious Diseases.

27 Apr 2005

Hemodialysis causes antioxidant loss leading to long-term complications

An article published in Hemodialysis International discusses the role of oxidative stress (OS) in dialysis patients, an imbalance which can result in long-term health problems. Potential therapeutic options to restore balance in patients are also reviewed.

10 Apr 2005